Armistice Capital, LLC 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:13 pm Purchase | 2024-09-30 | 13G | Travere Therapeutics, Inc. TVTX | Armistice Capital, LLC | 7,648,000 10.000% | 264,000 (+3.58%) | Filing |
| 2024-02-14 2:35 pm Purchase | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Armistice Capital, LLC | 7,384,000 9.830% | 972,000 (+15.16%) | Filing |
| 2023-02-14 1:39 pm Purchase | 2022-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Armistice Capital, LLC | 6,412,000 9.990% | 2,334,000 (+57.23%) | Filing |
| 2022-02-14 5:22 pm Purchase | 2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Armistice Capital, LLC | 4,078,000 6.700% | 4,078,000 (New Position) | Filing |